Health State Utility Values and Quality of Life in Patients Receiving Ripretinib in the Phase 3 Invictus Trial and a Real-World Evidence Study in China
Author(s)
Jones RL1, Blay JY2, Chi P3, Bauer S4, Gelderblom H5, Shen L6, He YL7, Heinrich MC8, Schöffski P9, Zalcberg JR10, Harrow B11, Sherman ML11, Ruiz-Soto R11, Becker C12, von Mehren M13
1Royal Marsden Hospital and Institute of Cancer Research, London, UK, 2Centre Léon Bérard, Lyon, France, 3Memorial Sloan Kettering Cancer Center, New York, NY, USA, 4Universitaetsklinikum Essen, Essen, Germany, 5Leids Universitair Medisch Centrum, Leiden, Netherlands, 6Peking University Cancer Hospital and Institute, Beijing, China, 7Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China, 8Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA, 9University Hospitals Leuven, Leuven, Belgium, 10The Alfred Hospital, Melbourne, Australia, 11Deciphera Pharmaceuticals, LLC, Waltham, MA, USA, 12Deciphera Pharmaceuticals, LLC, belmont, MA, USA, 13Fox Chase Cancer Center, Philadelphia, PA, USA
OBJECTIVES: Ripretinib is a switch-control tyrosine kinase inhibitor (TKI) approved for fourth-line (4L) treatment of patients with advanced gastrointestinal stromal tumor (GIST). In the INVICTUS study (NCT03353753) ripretinib demonstrated clinically meaningful benefit and a well-tolerated safety profile; patients reported stable or improved health-related quality of life (HRQoL) vs. placebo.1 We present health state utility values (HSUV) derived from EuroQol-5-Dimension (EQ-5D) questionnaires collected during both INVICTUS and a post-approval real-world evidence (RWE) study conducted in China.
METHODS: In INVICTUS, ≥4L GIST patients received ripretinib 150 mg (n=85) or placebo (n=44) once daily (QD).1 HRQoL was assessed using EQ-5D 5-Level (5L) at Day 1 of each cycle and end of treatment. Data were mapped using UK value sets to EQ-5D 3-Level (3L) utilities.2
In the RWE study, ≥4L GIST patients received ripretinib 150 mg QD (N=241). HRQoL was assessed monthly using EQ-5D-3L over 13 months. Data were mapped using Chinese value sets to EQ-5D-3L utilities.3 For both studies, mean HSUV were estimated for progression-free (PF) and progressed disease (PD) states.RESULTS: In INVICTUS, EQ-5D completion was >99%. HSUV for ripretinib vs. placebo were 0.75 vs. 0.73 for PF patients and 0.75 vs. 0.71 for PD patients. In the RWE study, EQ-5D completion was 65%. HSUV were 0.81 for PF patients and 0.67 for PD patients.
CONCLUSIONS: HSUV calculated from the INVICTUS study were higher for patients receiving ripretinib vs. placebo. HSUV calculated from the RWE survey were similar, indicating high HRQoL for patients receiving ripretinib both within a clinical trial and under real-world conditions. These HSUV may be used to inform economic evaluations of novel therapies for patients with advanced GIST.
REFERENCES: 1Blay JY et al. Lancet Oncol. 2020;21(7):923–34; 2van Hout B et al. Value Health. 2012;15(5):708–15; 3Liu GG et al. Value Health. 2014;17(5):597–604. FUNDING: Deciphera Pharmaceuticals, LLC. Medical writing by Costello Medical.Conference/Value in Health Info
Value in Health, Volume 25, Issue 12S (December 2022)
Acceptance Code
P61
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities
Disease
no-additional-disease-conditions-specialized-treatment-areas